APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant DNA Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Recombinant DNA Drug Market Analysis and Forecast 2026-2032

23 December 2025209 pages

Choose your research edition.

Industry ResearchRecombinant DNA Drug Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant DNA Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Recombinant DNA Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant DNA Drug Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant DNA Drug Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Recombinant DNA Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Recombinant DNA Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Recombinant DNA Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Recombinant DNA Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Recombinant DNA Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Recombinant DNA Drug include GenSci, Takeda, CSPC, 3SBIO, Sandoz, Sanofi, Johnson & Johnson, Novo Nordisk and Merck, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Recombinant DNA Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Recombinant DNA Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Recombinant DNA Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Recombinant DNA Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Recombinant DNA Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Recombinant DNA Drug revenue, projected growth trends, production technology, application and end-user industry.

Recombinant DNA Drug Segment by Company

GenSci

Takeda

CSPC

3SBIO

Sandoz

Sanofi

Johnson & Johnson

Novo Nordisk

Merck

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Biogen

Bayer

Bristol-Myers Squibb

Amgen

AbbVie

Swedish Orphan Biovitrum

Organon Pharma

Recombinant DNA Drug Segment by Type

Fusion Protein

Recombinant Interleukin

Recombinant Interferon

Recombinant Hormone

Recombinant Coagulation Factor

Recombinant Growth Factor

Other

Recombinant DNA Drug Segment by Application

Infectious Diseases

Metabolic Disorders

Cancers

Autoimmune Diseases

Recombinant DNA Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant DNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant DNA Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant DNA Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Recombinant DNA Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Recombinant DNA Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant DNA Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Recombinant DNA Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Fusion Protein Major Player Table 3. Recombinant Interleukin Major Player Table 4. Recombinant Interferon Major Player Table 5. Recombinant Hormone Major Player Table 6. Recombinant Coagulation Factor Major Player Table 7. Recombinant Growth Factor Major Player Table 8. Other Major Player Table 9. Global Recombinant DNA Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Infectious Diseases Major Player Table 11. Metabolic Disorders Major Player Table 12. Cancers Major Player Table 13. Autoimmune Diseases Major Player Table 14. Recombinant DNA Drug Industry Trends Table 15. Recombinant DNA Drug Industry Drivers Table 16. Recombinant DNA Drug Industry Opportunities and Challenges Table 17. Recombinant DNA Drug Industry Restraints Table 18. Global Recombinant DNA Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 19. Global Recombinant DNA Drug Market Size by Region (2021-2026) & (US$ Million) Table 20. Global Recombinant DNA Drug Market Share by Region (2021-2026) Table 21. Global Recombinant DNA Drug Market Size by Region (2027-2032) & (US$ Million) Table 22. Global Recombinant DNA Drug Market Share by Region (2027-2032) Table 23. Global Recombinant DNA Drug Revenue by Players (US$ Million) & (2021-2026) Table 24. Global Recombinant DNA Drug Revenue Market Share by Players (2021-2026) Table 25. Global Recombinant DNA Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 26. Global Recombinant DNA Drug Key Players Headquarters & Area Served Table 27. Global Recombinant DNA Drug Players, Product Type & Application Table 28. Global Recombinant DNA Drug Players Establishment Date Table 29. Global Players Market Concentration Ratio (CR5 and HHI) Table 30. Global Recombinant DNA Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 31. Global Recombinant DNA Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Recombinant DNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 33. Global Recombinant DNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 34. Global Recombinant DNA Drug Revenue Market Share by Type (2021-2026) Table 35. Global Recombinant DNA Drug Revenue Market Share by Type (2027-2032) Table 36. Global Recombinant DNA Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Recombinant DNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 38. Global Recombinant DNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 39. Global Recombinant DNA Drug Revenue Market Share by Application (2021-2026) Table 40. Global Recombinant DNA Drug Revenue Market Share by Application (2027-2032) Table 41. GenSci Company Information Table 42. GenSci Business Overview Table 43. GenSci Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. GenSci Recombinant DNA Drug Product Portfolio Table 45. GenSci Recent Development Table 46. Takeda Company Information Table 47. Takeda Business Overview Table 48. Takeda Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Takeda Recombinant DNA Drug Product Portfolio Table 50. Takeda Recent Development Table 51. CSPC Company Information Table 52. CSPC Business Overview Table 53. CSPC Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. CSPC Recombinant DNA Drug Product Portfolio Table 55. CSPC Recent Development Table 56. 3SBIO Company Information Table 57. 3SBIO Business Overview Table 58. 3SBIO Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. 3SBIO Recombinant DNA Drug Product Portfolio Table 60. 3SBIO Recent Development Table 61. Sandoz Company Information Table 62. Sandoz Business Overview Table 63. Sandoz Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Sandoz Recombinant DNA Drug Product Portfolio Table 65. Sandoz Recent Development Table 66. Sanofi Company Information Table 67. Sanofi Business Overview Table 68. Sanofi Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Sanofi Recombinant DNA Drug Product Portfolio Table 70. Sanofi Recent Development Table 71. Johnson & Johnson Company Information Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Johnson & Johnson Recombinant DNA Drug Product Portfolio Table 75. Johnson & Johnson Recent Development Table 76. Novo Nordisk Company Information Table 77. Novo Nordisk Business Overview Table 78. Novo Nordisk Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Novo Nordisk Recombinant DNA Drug Product Portfolio Table 80. Novo Nordisk Recent Development Table 81. Merck Company Information Table 82. Merck Business Overview Table 83. Merck Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Merck Recombinant DNA Drug Product Portfolio Table 85. Merck Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Roche Recombinant DNA Drug Product Portfolio Table 90. Roche Recent Development Table 91. Eli Lilly Company Information Table 92. Eli Lilly Business Overview Table 93. Eli Lilly Recombinant DNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Eli Lilly Recombinant DNA Drug Product Portfolio Table 95. Eli Lilly Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Recombinant DNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Pfizer Recombinant DNA Drug Product Portfolio Table 100. Pfizer Recent Development Table 101. GlaxoSmithKline Company Information Table 102. GlaxoSmithKline Business Overview Table 103. GlaxoSmithKline Recombinant DNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. GlaxoSmithKline Recombinant DNA Drug Product Portfolio Table 105. GlaxoSmithKline Recent Development Table 106. Biogen Company Information Table 107. Biogen Business Overview Table 108. Biogen Recombinant DNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Biogen Recombinant DNA Drug Product Portfolio Table 110. Biogen Recent Development Table 111. Bayer Company Information Table 112. Bayer Business Overview Table 113. Bayer Recombinant DNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Bayer Recombinant DNA Drug Product Portfolio Table 115. Bayer Recent Development Table 116. Bristol-Myers Squibb Company Information Table 117. Bristol-Myers Squibb Business Overview Table 118. Bristol-Myers Squibb Recombinant DNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Bristol-Myers Squibb Recombinant DNA Drug Product Portfolio Table 120. Bristol-Myers Squibb Recent Development Table 121. Amgen Company Information Table 122. Amgen Business Overview Table 123. Amgen Recombinant DNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Amgen Recombinant DNA Drug Product Portfolio Table 125. Amgen Recent Development Table 126. AbbVie Company Information Table 127. AbbVie Business Overview Table 128. AbbVie Recombinant DNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. AbbVie Recombinant DNA Drug Product Portfolio Table 130. AbbVie Recent Development Table 131. Swedish Orphan Biovitrum Company Information Table 132. Swedish Orphan Biovitrum Business Overview Table 133. Swedish Orphan Biovitrum Recombinant DNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Swedish Orphan Biovitrum Recombinant DNA Drug Product Portfolio Table 135. Swedish Orphan Biovitrum Recent Development Table 136. Organon Pharma Company Information Table 137. Organon Pharma Business Overview Table 138. Organon Pharma Recombinant DNA Drug Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Organon Pharma Recombinant DNA Drug Product Portfolio Table 140. Organon Pharma Recent Development Table 141. North America Recombinant DNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 142. North America Recombinant DNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 143. North America Recombinant DNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 144. North America Recombinant DNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 145. North America Recombinant DNA Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. North America Recombinant DNA Drug Revenue by Country (2021-2026) & (US$ Million) Table 147. North America Recombinant DNA Drug Revenue by Country (US$ Million) & (2027-2032) Table 148. Europe Recombinant DNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 149. Europe Recombinant DNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 150. Europe Recombinant DNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 151. Europe Recombinant DNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 152. Europe Recombinant DNA Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 153. Europe Recombinant DNA Drug Revenue by Country (2021-2026) & (US$ Million) Table 154. Europe Recombinant DNA Drug Revenue by Country (US$ Million) & (2027-2032) Table 155. China Recombinant DNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 156. China Recombinant DNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 157. China Recombinant DNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 158. China Recombinant DNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 159. Asia Recombinant DNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 160. Asia Recombinant DNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 161. Asia Recombinant DNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 162. Asia Recombinant DNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 163. Asia Recombinant DNA Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 164. Asia Recombinant DNA Drug Revenue by Region (US$ Million) & (2021-2026) Table 165. Asia Recombinant DNA Drug Revenue by Region (US$ Million) & (2027-2032) Table 166. SAMEA Recombinant DNA Drug Revenue by Type (2021-2026) & (US$ Million) Table 167. SAMEA Recombinant DNA Drug Revenue by Type (2027-2032) & (US$ Million) Table 168. SAMEA Recombinant DNA Drug Revenue by Application (2021-2026) & (US$ Million) Table 169. SAMEA Recombinant DNA Drug Revenue by Application (2027-2032) & (US$ Million) Table 170. SAMEA Recombinant DNA Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. SAMEA Recombinant DNA Drug Revenue by Country (2021-2026) & (US$ Million) Table 172. SAMEA Recombinant DNA Drug Revenue by Country (US$ Million) & (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Recombinant DNA Drug Image Figure 2. Global Recombinant DNA Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant DNA Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Fusion Protein Image Figure 5. Recombinant Interleukin Image Figure 6. Recombinant Interferon Image Figure 7. Recombinant Hormone Image Figure 8. Recombinant Coagulation Factor Image Figure 9. Recombinant Growth Factor Image Figure 10. Other Image Figure 11. Global Recombinant DNA Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Recombinant DNA Drug Market Size Share 2021 VS 2025 VS 2032 Figure 13. Infectious Diseases Image Figure 14. Metabolic Disorders Image Figure 15. Cancers Image Figure 16. Autoimmune Diseases Image Figure 17. Global Recombinant DNA Drug Market Size (US$ Million) & (2021-2032) Figure 18. Global Recombinant DNA Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Recombinant DNA Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 20. Global Recombinant DNA Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Recombinant DNA Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Recombinant DNA Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Recombinant DNA Drug Revenue Market Share by Type (2021-2032) Figure 25. Global Recombinant DNA Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Recombinant DNA Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 27. Global Recombinant DNA Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Recombinant DNA Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. North America Recombinant DNA Drug Revenue Share by Type (2021-2032) Figure 30. North America Recombinant DNA Drug Revenue Share by Application (2021-2032) Figure 31. North America Recombinant DNA Drug Revenue Share by Country (2021-2032) Figure 32. United States Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Canada Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Mexico Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Europe Recombinant DNA Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 36. Europe Recombinant DNA Drug Revenue Share by Type (2021-2032) Figure 37. Europe Recombinant DNA Drug Revenue Share by Application (2021-2032) Figure 38. Europe Recombinant DNA Drug Revenue Share by Country (2021-2032) Figure 39. Germany Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. France Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. U.K. Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Italy Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Spain Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Russia Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Netherlands Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Nordic Countries Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. China Recombinant DNA Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. China Recombinant DNA Drug Revenue Share by Type (2021-2032) Figure 49. China Recombinant DNA Drug Revenue Share by Application (2021-2032) Figure 50. Asia Recombinant DNA Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 51. Asia Recombinant DNA Drug Revenue Share by Type (2021-2032) Figure 52. Asia Recombinant DNA Drug Revenue Share by Application (2021-2032) Figure 53. Asia Recombinant DNA Drug Revenue Share by Region (2021-2032) Figure 54. Japan Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. South Korea Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. India Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Australia Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Taiwan Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Southeast Asia Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. SAMEA Recombinant DNA Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 61. SAMEA Recombinant DNA Drug Revenue Share by Type (2021-2032) Figure 62. SAMEA Recombinant DNA Drug Revenue Share by Application (2021-2032) Figure 63. SAMEA Recombinant DNA Drug Revenue Share by Country (2021-2032) Figure 64. Brazil Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Argentina Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Chile Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Colombia Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Peru Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Saudi Arabia Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Israel Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. UAE Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Turkey Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Iran Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Egypt Recombinant DNA Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Fusion Protein
  • Recombinant Interleukin
  • Recombinant Interferon
  • Recombinant Hormone
  • Recombinant Coagulation Factor
  • Recombinant Growth Factor
  • Other
Applications
  • Infectious Diseases
  • Metabolic Disorders
  • Cancers
  • Autoimmune Diseases
Companies covered
  • GenSci
  • Takeda
  • CSPC
  • 3SBIO
  • Sandoz
  • Sanofi
  • Johnson & Johnson
  • Novo Nordisk
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Bayer
  • Bristol-Myers Squibb
  • Amgen
  • AbbVie
  • Swedish Orphan Biovitrum
  • Organon Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Recombinant DNA Drug Market by Type
  3. 1.2.1 Global Recombinant DNA Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Fusion Protein
  5. 1.2.3 Recombinant Interleukin
  6. 1.2.4 Recombinant Interferon
  7. 1.2.5 Recombinant Hormone
  8. 1.2.6 Recombinant Coagulation Factor
  9. 1.2.7 Recombinant Growth Factor
  10. 1.2.8 Other
  11. 1.3 Recombinant DNA Drug Market by Application
  12. 1.3.1 Global Recombinant DNA Drug Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Infectious Diseases
  14. 1.3.3 Metabolic Disorders
  15. 1.3.4 Cancers
  16. 1.3.5 Autoimmune Diseases
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Recombinant DNA Drug Market Dynamics
  1. 2.1 Recombinant DNA Drug Industry Trends
  2. 2.2 Recombinant DNA Drug Industry Drivers
  3. 2.3 Recombinant DNA Drug Industry Opportunities and Challenges
  4. 2.4 Recombinant DNA Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Recombinant DNA Drug Market Perspective (2021-2032)
  2. 3.2 Global Recombinant DNA Drug Growth Trends by Region
  3. 3.2.1 Global Recombinant DNA Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Recombinant DNA Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Recombinant DNA Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Recombinant DNA Drug Revenue by Players
  2. 4.1.1 Global Recombinant DNA Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Recombinant DNA Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Recombinant DNA Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Recombinant DNA Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Recombinant DNA Drug Key Players Headquarters & Area Served
  7. 4.4 Global Recombinant DNA Drug Players, Product Type & Application
  8. 4.5 Global Recombinant DNA Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Recombinant DNA Drug Market CR5 and HHI
  11. 4.6.3 2025 Recombinant DNA Drug Tier 1, Tier 2, and Tier 3
5 Recombinant DNA Drug Market Size by Type
  1. 5.1 Global Recombinant DNA Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Recombinant DNA Drug Revenue by Type (2021-2032)
  3. 5.3 Global Recombinant DNA Drug Revenue Market Share by Type (2021-2032)
6 Recombinant DNA Drug Market Size by Application
  1. 6.1 Global Recombinant DNA Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Recombinant DNA Drug Revenue by Application (2021-2032)
  3. 6.3 Global Recombinant DNA Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GenSci
  2. 7.1.1 GenSci Company Information
  3. 7.1.2 GenSci Business Overview
  4. 7.1.3 GenSci Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GenSci Recombinant DNA Drug Product Portfolio
  6. 7.1.5 GenSci Recent Developments
  7. 7.2 Takeda
  8. 7.2.1 Takeda Company Information
  9. 7.2.2 Takeda Business Overview
  10. 7.2.3 Takeda Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Recombinant DNA Drug Product Portfolio
  12. 7.2.5 Takeda Recent Developments
  13. 7.3 CSPC
  14. 7.3.1 CSPC Company Information
  15. 7.3.2 CSPC Business Overview
  16. 7.3.3 CSPC Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 CSPC Recombinant DNA Drug Product Portfolio
  18. 7.3.5 CSPC Recent Developments
  19. 7.4 3SBIO
  20. 7.4.1 3SBIO Company Information
  21. 7.4.2 3SBIO Business Overview
  22. 7.4.3 3SBIO Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 3SBIO Recombinant DNA Drug Product Portfolio
  24. 7.4.5 3SBIO Recent Developments
  25. 7.5 Sandoz
  26. 7.5.1 Sandoz Company Information
  27. 7.5.2 Sandoz Business Overview
  28. 7.5.3 Sandoz Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sandoz Recombinant DNA Drug Product Portfolio
  30. 7.5.5 Sandoz Recent Developments
  31. 7.6 Sanofi
  32. 7.6.1 Sanofi Company Information
  33. 7.6.2 Sanofi Business Overview
  34. 7.6.3 Sanofi Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Sanofi Recombinant DNA Drug Product Portfolio
  36. 7.6.5 Sanofi Recent Developments
  37. 7.7 Johnson & Johnson
  38. 7.7.1 Johnson & Johnson Company Information
  39. 7.7.2 Johnson & Johnson Business Overview
  40. 7.7.3 Johnson & Johnson Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Johnson & Johnson Recombinant DNA Drug Product Portfolio
  42. 7.7.5 Johnson & Johnson Recent Developments
  43. 7.8 Novo Nordisk
  44. 7.8.1 Novo Nordisk Company Information
  45. 7.8.2 Novo Nordisk Business Overview
  46. 7.8.3 Novo Nordisk Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Novo Nordisk Recombinant DNA Drug Product Portfolio
  48. 7.8.5 Novo Nordisk Recent Developments
  49. 7.9 Merck
  50. 7.9.1 Merck Company Information
  51. 7.9.2 Merck Business Overview
  52. 7.9.3 Merck Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Merck Recombinant DNA Drug Product Portfolio
  54. 7.9.5 Merck Recent Developments
  55. 7.10 Roche
  56. 7.10.1 Roche Company Information
  57. 7.10.2 Roche Business Overview
  58. 7.10.3 Roche Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Roche Recombinant DNA Drug Product Portfolio
  60. 7.10.5 Roche Recent Developments
  61. 7.11 Eli Lilly
  62. 7.11.1 Eli Lilly Company Information
  63. 7.11.2 Eli Lilly Business Overview
  64. 7.11.3 Eli Lilly Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Eli Lilly Recombinant DNA Drug Product Portfolio
  66. 7.11.5 Eli Lilly Recent Developments
  67. 7.12 Pfizer
  68. 7.12.1 Pfizer Company Information
  69. 7.12.2 Pfizer Business Overview
  70. 7.12.3 Pfizer Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Pfizer Recombinant DNA Drug Product Portfolio
  72. 7.12.5 Pfizer Recent Developments
  73. 7.13 GlaxoSmithKline
  74. 7.13.1 GlaxoSmithKline Company Information
  75. 7.13.2 GlaxoSmithKline Business Overview
  76. 7.13.3 GlaxoSmithKline Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 GlaxoSmithKline Recombinant DNA Drug Product Portfolio
  78. 7.13.5 GlaxoSmithKline Recent Developments
  79. 7.14 Biogen
  80. 7.14.1 Biogen Company Information
  81. 7.14.2 Biogen Business Overview
  82. 7.14.3 Biogen Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Biogen Recombinant DNA Drug Product Portfolio
  84. 7.14.5 Biogen Recent Developments
  85. 7.15 Bayer
  86. 7.15.1 Bayer Company Information
  87. 7.15.2 Bayer Business Overview
  88. 7.15.3 Bayer Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Bayer Recombinant DNA Drug Product Portfolio
  90. 7.15.5 Bayer Recent Developments
  91. 7.16 Bristol-Myers Squibb
  92. 7.16.1 Bristol-Myers Squibb Company Information
  93. 7.16.2 Bristol-Myers Squibb Business Overview
  94. 7.16.3 Bristol-Myers Squibb Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Bristol-Myers Squibb Recombinant DNA Drug Product Portfolio
  96. 7.16.5 Bristol-Myers Squibb Recent Developments
  97. 7.17 Amgen
  98. 7.17.1 Amgen Company Information
  99. 7.17.2 Amgen Business Overview
  100. 7.17.3 Amgen Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Amgen Recombinant DNA Drug Product Portfolio
  102. 7.17.5 Amgen Recent Developments
  103. 7.18 AbbVie
  104. 7.18.1 AbbVie Company Information
  105. 7.18.2 AbbVie Business Overview
  106. 7.18.3 AbbVie Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 AbbVie Recombinant DNA Drug Product Portfolio
  108. 7.18.5 AbbVie Recent Developments
  109. 7.19 Swedish Orphan Biovitrum
  110. 7.19.1 Swedish Orphan Biovitrum Company Information
  111. 7.19.2 Swedish Orphan Biovitrum Business Overview
  112. 7.19.3 Swedish Orphan Biovitrum Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Swedish Orphan Biovitrum Recombinant DNA Drug Product Portfolio
  114. 7.19.5 Swedish Orphan Biovitrum Recent Developments
  115. 7.20 Organon Pharma
  116. 7.20.1 Organon Pharma Company Information
  117. 7.20.2 Organon Pharma Business Overview
  118. 7.20.3 Organon Pharma Recombinant DNA Drug Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Organon Pharma Recombinant DNA Drug Product Portfolio
  120. 7.20.5 Organon Pharma Recent Developments
8 North America
  1. 8.1 North America Recombinant DNA Drug Revenue (2021-2032)
  2. 8.2 North America Recombinant DNA Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Recombinant DNA Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Recombinant DNA Drug Revenue by Type (2027-2032)
  5. 8.3 North America Recombinant DNA Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Recombinant DNA Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Recombinant DNA Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Recombinant DNA Drug Revenue by Application (2027-2032)
  9. 8.5 North America Recombinant DNA Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Recombinant DNA Drug Revenue by Country
  11. 8.6.1 North America Recombinant DNA Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Recombinant DNA Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Recombinant DNA Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Recombinant DNA Drug Revenue (2021-2032)
  2. 9.2 Europe Recombinant DNA Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Recombinant DNA Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Recombinant DNA Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Recombinant DNA Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Recombinant DNA Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Recombinant DNA Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Recombinant DNA Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Recombinant DNA Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Recombinant DNA Drug Revenue by Country
  11. 9.6.1 Europe Recombinant DNA Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Recombinant DNA Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Recombinant DNA Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Recombinant DNA Drug Revenue (2021-2032)
  2. 10.2 China Recombinant DNA Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Recombinant DNA Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Recombinant DNA Drug Revenue by Type (2027-2032)
  5. 10.3 China Recombinant DNA Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Recombinant DNA Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Recombinant DNA Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Recombinant DNA Drug Revenue by Application (2027-2032)
  9. 10.5 China Recombinant DNA Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Recombinant DNA Drug Revenue (2021-2032)
  2. 11.2 Asia Recombinant DNA Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Recombinant DNA Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Recombinant DNA Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Recombinant DNA Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Recombinant DNA Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Recombinant DNA Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Recombinant DNA Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Recombinant DNA Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Recombinant DNA Drug Revenue by Country
  11. 11.6.1 Asia Recombinant DNA Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Recombinant DNA Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Recombinant DNA Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Recombinant DNA Drug Revenue (2021-2032)
  2. 12.2 SAMEA Recombinant DNA Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Recombinant DNA Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Recombinant DNA Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Recombinant DNA Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Recombinant DNA Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Recombinant DNA Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Recombinant DNA Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Recombinant DNA Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Recombinant DNA Drug Revenue by Country
  11. 12.6.1 SAMEA Recombinant DNA Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Recombinant DNA Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Recombinant DNA Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst